|
|
|
原研机构- |
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis
100 项与 Psyence Australia Pty Ltd. 相关的临床结果
0 项与 Psyence Australia Pty Ltd. 相关的专利(医药)
100 项与 Psyence Australia Pty Ltd. 相关的药物交易
100 项与 Psyence Australia Pty Ltd. 相关的转化医学